Portal de investigação
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- D'Amico, F
- Solitano, V
- Olivera, PA
- Halfvarson, J
- Rubin, D
- Dignass, A
- Al Awadhi, S
- Kobayashi, T
- Queiroz, NSF
- Calvo, M
- Kotze, PG
- Ghosh, S
- Peyrin-Biroulet, L
- Danese, S
Unidades de investigação
Abstract
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians' current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption-whether initiating a biosimilar, transitioning from an originator to a biosimilar, or switching between biosimilars (including multiple switches and reverse switching)-a global survey was conducted. Fifteen physicians with expertise in the field of IBD from 13 countries attended a virtual international consensus meeting to develop practical guidance regarding biosimilar adoption worldwide, considering the survey results. This consensus centered on 10 key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring of biosimilars, non-medical switching, and future perspectives. Ultimately, the consensus affirmed that biosimilars are equally effective and safe when compared to originator drugs. They are considered suitable for both biologic-naive patients and those who have previously been treated with originator drugs, with cost reduction being the primary motivation for transitioning from an originator drug to a biosimilar.
Dados da publicação
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm12196350
- Link para outro recurso:
- www.scopus.com
Journal of Clinical Medicine MDPI AG
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 7
Documentos
- Não há documentos
Filiações
Keywords
- biosimilars; bio-originators; biologic drug; IBD; ulcerative colitis; Crohn's disease; interchangeability; economics
Financiamento
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Burden of Inflammatory Bowel Disease in Portugal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico (Inflammatory Bowel) . 2023
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
D'Amico F,Solitano V,Magro F,Olivera PA,Halfvarson J,Rubin D,Dignass A,Al Awadhi S,Kobayashi T,Queiroz NSF,Calvo M,Kotze PG,Ghosh S,Peyrin L,Danese S. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. J. Clin. Med. 2023. 12. (19):6350. IF:3,900. (2).
